AMLo Biosciences’ Post

In recognition of #MelanomaAwarenessMonth, AMLo Biosciences are sharing (to US-only audience) a patient case study demonstrating the clinical utility of their #AMBLor technology that accurately stratifies early-stage, low-risk melanomas. https://lnkd.in/eehgYpVY AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers

Just a reminder that Professor Phil Sloan and Dr Akhtar Husain, our leading pathology experts, are in the US attending the American Society of Dermatology Annual Meeting 7-10 November #ASDP24. They would be happy to meet and discuss #AMBLor, our biomarker prognostic that accurately identifies early-stage melanomas at low risk of progression. Find out more about how using this test can personalise melanoma management through effective use of further diagnostic procedures and follow-ups, and help ease patient anxiety. Please message Alex Pogorzelski at inquiries@usa.amlo-biosciences.com to arrange a time to chat. Professor Sloan and Dr Husain are also presenting new research on the use of AMBLor technology in #melanoma in situ, #atypicallesions and #spitznaevi, which we hope will lead to further improvements for clinicians to better manage their patients. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. #AMBLor has received its UKCA mark in the UK. #dermatology #histopathology #oncology #skincancer #biomarkers #cancerresreach #dermatopathology #PathologyMatters #PathologyAwareness

We were interested to read an article published in Dermatology and Therapy emphasising the need to find disease-specific #biomarkers for #skincancer. The review focuses on molecular and histologic biomarkers that are relevant to patient management, including prevention/risk assessments, tumour diagnosis, and therapy selection. https://bit.ly/3WgvtQI Here at AMLo Biosciences we have developed our biomarker technology, #AMBLor, that accurately identifies early-stage #melanomas at low-risk of progression. This prognostic information can risk-stratify melanomas helping clinical decision makers with personalised disease management and follow-up. Find out more: www.amlo-biosciences.com   AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. The AMBRA1 and loricrin test is available in the UK as a UKAS accredited LDT. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers 

Photobiomodulation Therapy: A New Horizon in Melasma Treatment Photobiomodulation therapy (PBM), a versatile technique in the field of skin disease treatment, is gaining attention. Especially when it comes to treating melasma, a chronic hyperpigmentation condition, PBM is showing significant potential. Recent research suggests that the development of melasma is associated with vascular features and dermal photoaging, posing significant treatment challenges. However, PBM, with its unique approach, offers new possibilities. We conducted a comprehensive review of the literature over the past decade and identified nine relevant studies on PBM for melasma treatment. These studies include clinical trials, in vitro experiments, and animal model research. The results suggest that PBM can effectively reduce the hyperpigmentation associated with melasma. Specific wavelengths (red: 630 nm; amber: 585 and 590 nm; infrared: 830 and 850 nm) at radiant exposures between 1 and 20 J/cm2 can modulate tyrosinase activity, affecting the gene expression and protein synthesis of melanocytic pathway components, thereby significantly reducing melanin content. Additionally, PBM can improve the dermal structure, reduce erythema and neovascularization, which are pathological components of melasma. Therefore, PBM is considered a promising, modern, and non-invasive procedure for treating melasma. Beyond its role in inhibiting melanogenesis, PBM also shows potential in reducing erythema and vascularization and improving dermal conditions. Source: https://bit.ly/3Q8hPgg #Photobiomodulation #MelasmaTreatment #SkinCare #Dermatology #Hyperpigmentation #ClinicalTrials #MedicalInnovation #NonInvasiveTherapy #PBM #kaiyanMedical

Researchers at the Australian National University have developed a new #AI technology to help clinicians identify the most suitable treatment for a range of different cancers. This AI uses #histopathology images from tumours to reduce the current delays in processing complex molecular data needed to identify the best therapy. https://bit.ly/3Wd6JtM At AMLo Biosciences, our team continue working to integrate AI into our prognostic technology #AMBLor, that accurately identifies early-stage melanomas at low risk of progression. The addition of AI will ensure an added second opinion to our already robust testing solution. AMBLor® testing service is provided by @Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. The AMBRA1 and loricrin test is available in the UK as an LDT. www.amlo-biosciences.com #dermatology #dermatopathology #oncology #skincancer #cancerresearch #biomarkers

🌟 Exciting News from Symmetron! 🌟 📢 The 2023 update of the EULAR recommendations for psoriatic arthritis (PsA) management have arrived with new guidelines, including 7 overarching principles and 11 recommendations driven by developments in drug safety and efficacy. A special shoutout to our Symmetron colleagues for authoring the network meta-analysis (NMA) cited as providing the key comparative efficacy evidence for biologic and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs). 👏 Join us in celebrating these advancements for better patient outcomes. 📈 🔗 Follow the link in the comments to dive into the details! 🔗 #HEOR #Research #Dermatology

I am excited to share a recent case study exploring the dermatologic side effects associated with amivantamab, a bispecific antibody used in cancer treatment. Despite initial interventions, the patient experienced significant scalp ulceration and hair sloughing, leading to a multidisciplinary approach involving dermatology and infectious disease specialists. Through careful diagnostic exclusion and a review of similar case reports, amivantamab was identified as the likely cause. This case highlights the importance of tailored care and the need for vigilance in recognizing and managing drug-related dermatologic toxicities in oncology patients. I hope this study provides valuable insights for clinicians navigating similar challenges in their practice. #Oncology #Dermatology #Amivantamab #CaseStudy #MedicalResearch #PatientCare

Are you exploring treatment options for Atopic Dermatitis, Psoriasis or Sarcoidosis? GENEActiv can add significant value to your clinical research as it can detect and quantify fine motor movements which can provide valuable insight into the effectiveness of treatments. Unlock the potential to understand treatment impact: https://lnkd.in/eW3fYH76 #DermatologyResearch #ClinicalTrials

We recently we had the great pleasure of meeting with some of the world’s leading experts in the fields of #Dermatology and #AtopicDermatitis, to discuss clinical development plans for the lead candidate in our pipeline of disease-modifying #Therapies for chronic #Autoimmune and #InflammatoryDiseases. SYX-5219, which will advance into the clinic for the treatment of atopic dermatitis, targets a critical enzyme regulating cell #Metabolism called pyruvate kinase M2 (PKM2) – a novel therapeutic target with the potential to rebalance the #ImmuneSystem, normalize immune cell function and drive sustained disease remission.    As we finalise our development plans for this candidate, it’s vital that we collaborate with, and learn from, those who are expert in the field and those who are treating patients today. A huge thank you to everyone who shared their time, knowledge, insights and real-world experiences – invaluable to us in ensuring our #Science can continue to progress at pace for the benefit of patients.   Find out more about the latest progress within Sitryx’s proprietary pipeline: https://lnkd.in/eS8FGNRx

Did you know? ·      Approx 95% of all clinical pathways rely on patients having access to pathology services. ·      300,000 pathology tests are performed every working day in the UK. ·      50 million reports are sent from labs to GPs every year. This week, The Royal College of Pathologists host National #PathologyWeek, an annual celebration of pathology that highlights the vital contribution pathologists make to healthcare. AMLo Biosciences are proud to play a role in the #dermatopathology of #melanoma with #AMBLor, our biomarker prognostic that identifies early-stage low-risk melanomas. With the additional information from this test, clinicians can make more informed decisions about further invasive procedures, follow-up schedules and offer reassurance to patients around disease progression. AMBLor has received its UKCA mark and is now available to healthcare professionals. https://lnkd.in/evB_--5z #PathologistsAndPatients #dermatology #histopathology #oncology #skincancer #biomarkers #cancerresreach